Ardelyx, Inc. ARDX
Biotechnology: Pharmaceutical Preparations · IPO 2014 · data as of November 13, 2026
Ardelyx, Inc. (ARDX) is a healthcare company listed in the US with a market value of about $777M. In the twelve months to September 30, 2026 it had revenue of $468M and net income of -$55M, a net margin of -11.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 122% a year, a 5-year average ROIC of -34%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 42% below the current price.
About Ardelyx
Ardelyx is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2014. Revenue went from $32M in 2014 to $407M in 2025, growth of about 26.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 52% over three years (dilution for shareholders). It spends 18% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $468M | $407M | $334M | $124M | $52M | $10M | $8M | $5M | $3M | $42M | — |
| Net income | -$55M | -$62M | -$39M | -$66M | -$67M | -$158M | -$94M | -$95M | -$91M | -$64M | -$112M |
| Free cash flow | -$16M | -$44M | -$46M | -$90M | -$70M | -$154M | -$82M | -$77M | -$71M | -$68M | -$97M |
| EPS (diluted) | $-0.23 | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 | $-1.05 | $-1.47 | $-1.62 | $-1.36 | $-2.80 |
| Net margin | -11.8% | -15.1% | -11.7% | -53.1% | -128.8% | -1566.5% | -1245.7% | -1797.8% | -3502.0% | -153.2% | — |
| ROIC | — | -8.6% | -6.8% | -22.4% | -37.4% | -95.2% | -40.0% | -29.9% | -42.8% | -36.9% | -46.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $12.50, 305% above the current price; targets range from $8.00 to $18.00; the consensus rating is “Strong buy”; expected EPS is $-0.20 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Ardelyx stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 42% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ardelyx pay a dividend?
Not currently.
Is Ardelyx a good stock to buy?
We do not give buy or sell advice. Ardelyx scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.